MedPageToday -- DENVER -- Patients with diabetic nephropathy had significant reductions in residual albuminuria when the endothelin antagonist atrasentan (Xinlay) was added to ACE inhibitor or angiotensin receptor blocker (ARB) therapy, data from a small placebo-controlled trial showed.
